June 28, 2018
1 min read
Save

Top stories in hematology/oncology: Flight attendants at increased risk for several cancers, new promising treatment for head and neck squamous cell carcinoma

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Among the top stories in hematology/oncology is a report that flight attendants had elevated risks of several types of cancer. Patients with head and neck squamous cell carcinoma experienced “excellent” outcomes with neoadjuvant chemotherapy and surgery followed by risk-adapted adjuvant therapy. Other top stories include a column in which the role of nurse practitioners in pain and symptom management is discussed, a combination of ibrutinib and rituximab for the treatment of patients with Waldenström’s macroglobulinemia was granted priority review by the FDA, and Cincinnati Children’s Hospital Medical Center was named the nation’s best hospital for children with cancer.

Flight attendants at increased risk for breast, skin cancers

Flight attendants showed elevated incidence of several types of cancer compared with the general population, according to findings published in Environmental Health. Read More.

Researchers identify promising treatment regimen for head and neck squamous cell carcinoma

Neoadjuvant chemotherapy and surgery followed by risk-adapted adjuvant therapy produced “excellent” outcomes among patients with head and neck squamous cell carcinoma, study data showed. Read More.

Nurse practitioners play an important role in oncology pain, symptom management

Nurse practitioners provide pain and symptom management support for acutely ill patients with cancer in the hospital, as well as for stable yet chronically ill outpatients, whether they are actively receiving treatment, under surveillance or are cancer survivors. Read More.

FDA grants priority review to Imbruvica-Rituxan combination for Waldenström’s macroglobulinemia

The FDA granted priority review to the supplemental new drug application for ibrutinib in combination with rituximab for the treatment of patients with Waldenström’s macroglobulinemia, according to the manufacturer. Read More.

Cincinnati Children’s Hospital Medical Center named nation’s best for pediatric cancer

Cincinnati Children’s Hospital Medical Center has been named the best hospital in the nation for children with cancer. Read More.